Please login to the form below

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

The year saw it spend $8.7bn on acquiring gene therapy company AveXis and radiotherapy specialists Endocyte for $2.8bn.

Novartis: pipeline will generate 60 filings in three years

Endocyte adding .
Novartis culls pipeline to focus on most transformative science

$8.7bn, and cancer specialist Endocyte for $2.1bn.
Novartis buys cancer specialist Endocyte for $2.1bn

Heading up Endocyte’s pipeline is. 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). ... Novartis said radiopharma is a “key growth driver” for its business and that
Merck's vintafolide fails ovarian cancer trial

If vintafolide is dropped, Endocyte will have to refocus its efforts on EC1456, a cancer drug for folate receptor-positive cancers in phase I testing. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last
EMA backs Janssen rare disease drug for approval

it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Deal Watch October 2018

Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the tumour through a tumour‐targeted ligand.
Charting a course for expansion

and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly. Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma ... In addition, Endocyte says it has three new drug
Endocyte brings in senior figures from BMS and Amgen

The appointments come at a crucial time for Endocyte as it prepares for the approval and launch of cancer drugs vintafolide (in partnership with Merck &Co) and etarfolatide. ... The two additions follow the hire in July 2012 of Endocyte's first chief

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Empowered patients: shaking the foundations of healthcare: Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service: The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....